• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种新型半胱氨酸丰富肽利那洛肽的区域选择性合成。

A New Regioselective Synthesis of the Cysteine-Rich Peptide Linaclotide.

机构信息

State Key Laboratory of NBC Protection for Civilian, Beijing 102205, China.

School of Chemistry Engineering, Sichuan University of Science & Engineering, Zigong 643000, China.

出版信息

Molecules. 2023 Jan 19;28(3):1007. doi: 10.3390/molecules28031007.

DOI:10.3390/molecules28031007
PMID:36770675
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9919235/
Abstract

Linaclotide is a 14-amino acid residue peptide approved by the FDA for the treatment of irritable bowel syndrome with constipation (IBS-C), which activates guanylate cyclase C to accelerate intestinal transit. Here we show a new method for the synthesis of linaclotide through the completely selective formation of three disulfide bonds in satisfactory overall yields via mild oxidation reactions of the solid phase and liquid phase, using 4-methoxytrityl (Mmt), diphenylmethyl (Dpm) and 2-nitrobenzyl (O-NBn) protecting groups of cysteine as substrate, respectively.

摘要

利那洛肽是一种 14 个氨基酸残基肽,经 FDA 批准用于治疗便秘型肠易激综合征(IBS-C),可激活鸟苷酸环化酶 C 以加速肠道转运。在此,我们展示了一种通过固相和液相温和氧化反应,以完全选择性方式形成三个二硫键的新方法,在令人满意的总收率下合成利那洛肽,使用 4-甲氧基三苯甲基(Mmt)、二苯甲基(Dpm)和 2-硝基苄基(O-NBn)作为半胱氨酸的保护基团。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f235/9919235/06a8bc11cbed/molecules-28-01007-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f235/9919235/55174c231524/molecules-28-01007-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f235/9919235/e74d65d1b8a7/molecules-28-01007-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f235/9919235/006f5cd0f0fd/molecules-28-01007-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f235/9919235/06a8bc11cbed/molecules-28-01007-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f235/9919235/55174c231524/molecules-28-01007-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f235/9919235/e74d65d1b8a7/molecules-28-01007-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f235/9919235/006f5cd0f0fd/molecules-28-01007-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f235/9919235/06a8bc11cbed/molecules-28-01007-g004.jpg

相似文献

1
A New Regioselective Synthesis of the Cysteine-Rich Peptide Linaclotide.一种新型半胱氨酸丰富肽利那洛肽的区域选择性合成。
Molecules. 2023 Jan 19;28(3):1007. doi: 10.3390/molecules28031007.
2
Linaclotide: a novel agent for chronic constipation and irritable bowel syndrome.利那洛肽:一种用于治疗慢性便秘和肠易激综合征的新型药物。
Am J Health Syst Pharm. 2014 Jul 1;71(13):1081-91. doi: 10.2146/ajhp130575.
3
Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit.利那洛肽通过激活肠上皮细胞表面的鸟苷酸环化酶 C,在胃肠道局部发挥作用,刺激肠道分泌和运动。
Eur J Pharmacol. 2010 Dec 15;649(1-3):328-35. doi: 10.1016/j.ejphar.2010.09.019. Epub 2010 Sep 20.
4
Efficacy and Tolerability of Guanylate Cyclase-C Agonists for Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation: A Systematic Review and Meta-Analysis.鸟苷酸环化酶 C 激动剂治疗便秘型肠易激综合征和慢性特发性便秘的疗效和耐受性:系统评价和荟萃分析。
Am J Gastroenterol. 2018 Mar;113(3):329-338. doi: 10.1038/ajg.2017.495. Epub 2018 Jan 30.
5
Linaclotide in irritable bowel syndrome with constipation: A Phase 3 randomized trial in China and other regions.Linaclotide 治疗便秘型肠易激综合征的 3 期随机临床试验:中国及其他地区研究结果
J Gastroenterol Hepatol. 2018 May;33(5):980-989. doi: 10.1111/jgh.14086. Epub 2018 Mar 12.
6
Pharmacologic properties, metabolism, and disposition of linaclotide, a novel therapeutic peptide approved for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation.利那洛肽的药理学特性、代谢和处置,一种新型治疗肽,用于治疗便秘型肠易激综合征和慢性特发性便秘。
J Pharmacol Exp Ther. 2013 Jan;344(1):196-206. doi: 10.1124/jpet.112.199430. Epub 2012 Oct 22.
7
Review article: Linaclotide for the management of irritable bowel syndrome with constipation.综述文章:利那洛肽治疗便秘型肠易激综合征。
Aliment Pharmacol Ther. 2014 Feb;39(4):371-84. doi: 10.1111/apt.12604. Epub 2014 Jan 16.
8
A review of the clinical efficacy of linaclotide in irritable bowel syndrome with constipation.一项关于利那洛肽治疗便秘型肠易激综合征的临床疗效的综述。
Curr Med Res Opin. 2013 Feb;29(2):149-60. doi: 10.1185/03007995.2012.754743. Epub 2012 Dec 20.
9
[Pharmacological and clinical profile of linaclotide (Linzess), a novel therapeutic agent for irritable bowel syndrome with constipation and chronic constipation].[利那洛肽(Linzess)的药理及临床概况,一种用于治疗便秘型肠易激综合征和慢性便秘的新型治疗药物]
Nihon Yakurigaku Zasshi. 2019;153(6):289-298. doi: 10.1254/fpj.153.289.
10
Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety.Linaclotide 治疗便秘型肠易激综合征的 26 周随机、双盲、安慰剂对照试验:评估疗效和安全性。
Am J Gastroenterol. 2012 Nov;107(11):1702-12. doi: 10.1038/ajg.2012.254.

引用本文的文献

1
An improved synthesis of Compound 11, a unique bicyclic melanocortin-3 antagonist.化合物11(一种独特的双环促黑素皮质激素-3拮抗剂)的改进合成方法。
Pept Sci (Hoboken). 2025 Jan;117(1). doi: 10.1002/pep2.24385. Epub 2024 Nov 22.
2
Fenchone Ameliorates Constipation-Predominant Irritable Bowel Syndrome via Modulation of SCF/c-Kit Pathway and Gut Microbiota.葎草酮通过调节 SCF/c-Kit 通路和肠道微生物群改善便秘型肠易激综合征。
J Microbiol Biotechnol. 2024 Feb 28;34(2):367-378. doi: 10.4014/jmb.2308.08011. Epub 2023 Oct 28.

本文引用的文献

1
Importance of Non-pharmacological Approaches for Treating Irritable Bowel Syndrome: Mechanisms and Clinical Relevance.非药物治疗方法对肠易激综合征的重要性:作用机制及临床意义
Front Pain Res (Lausanne). 2021 Jan 21;1:609292. doi: 10.3389/fpain.2020.609292. eCollection 2020.
2
General synthetic strategy for regioselective ultrafast formation of disulfide bonds in peptides and proteins.在肽和蛋白质中区域选择性超快形成二硫键的通用合成策略。
Nat Commun. 2021 Feb 8;12(1):870. doi: 10.1038/s41467-021-21209-0.
3
EGF-like and Other Disulfide-rich Microdomains as Therapeutic Scaffolds.
EGF 样和其他富含二硫键的微区作为治疗性支架。
Angew Chem Int Ed Engl. 2020 Jul 6;59(28):11218-11232. doi: 10.1002/anie.201913809. Epub 2020 Mar 2.
4
Cyclotides: From Structure to Function.环肽:从结构到功能。
Chem Rev. 2019 Dec 26;119(24):12375-12421. doi: 10.1021/acs.chemrev.9b00402. Epub 2019 Dec 12.
5
Conotoxins: Chemistry and Biology.神经毒素:化学与生物学。
Chem Rev. 2019 Nov 13;119(21):11510-11549. doi: 10.1021/acs.chemrev.9b00207. Epub 2019 Oct 21.
6
Multifaceted roles of disulfide bonds. Peptides as therapeutics.二硫键的多方面作用。作为治疗药物的肽。
Chem Rev. 2014 Jan 22;114(2):901-26. doi: 10.1021/cr400031z. Epub 2013 Oct 29.
7
Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-C and extracellular cyclic guanosine 3',5'-monophosphate.利那洛肽通过鸟苷酸环化酶 C 和细胞外环鸟苷酸 3',5'-单磷酸抑制结肠伤害感受器,缓解腹痛。
Gastroenterology. 2013 Dec;145(6):1334-46.e1-11. doi: 10.1053/j.gastro.2013.08.017. Epub 2013 Aug 16.
8
Protein folding: Turbo-charged crosslinking.蛋白质折叠:加速交联
Nat Chem. 2012 Jul 24;4(8):600-2. doi: 10.1038/nchem.1417.
9
Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit.利那洛肽通过激活肠上皮细胞表面的鸟苷酸环化酶 C,在胃肠道局部发挥作用,刺激肠道分泌和运动。
Eur J Pharmacol. 2010 Dec 15;649(1-3):328-35. doi: 10.1016/j.ejphar.2010.09.019. Epub 2010 Sep 20.
10
Optimized Fmoc solid-phase synthesis of the cysteine-rich peptide linaclotide.优化的 Fmoc 固相合成富含半胱氨酸的肤拉菌素。
Biopolymers. 2011;96(1):69-80. doi: 10.1002/bip.21480. Epub 2010 Aug 21.